Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.67 |
| ▸ | CES1 | P23141 | 2/20 | 0.67 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.49 |
| ▸ | CHRNG | P07510 | 1/20 | 0.49 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | CHRND | Q07001 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29669896 | 1.00 | CES2 (0.67) | CES2CES1MAOAMAOBRAB9A | |
| SCHEMBL8913485 | 0.83 | KIF11 (0.67) | CES2CES1MAOAMAOBRAB9A | |
| Pimagedine SCHEMBL27957183 | 0.82 | CES2 (0.47) | CES2CES1MAOAMAOBRAB9A | |
| SCHEMBL29818197 | 0.82 | HSD17B14 (0.53) | CES2CES1MAOAMAOBRAB9A | |
| SCHEMBL661197 | 0.82 | PKM (0.55) | CES2CES1RAB9ANPC1MAPT | |
| SCHEMBL29602493 | 0.82 | PIM1 (0.47) | CES2CES1MAOAMAOBRAB9A | |
| SCHEMBL6562864 | 0.82 | MAOB (0.46) | CES2CES1MAOAMAOBRAB9A | |
| SCHEMBL658959 | 0.82 | HSD17B14 (0.53) | CES2CES1MAOAMAOBRAB9A | |
| SCHEMBL30881474 | 0.82 | HDAC1 (0.63) | CES2CES1RAB9AKMT2ANPC1 | |
| SCHEMBL1924482 | 0.82 | PIM1 (0.47) | CES2CES1MAOAMAOBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 771 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116262673-B | Preparation method of alpha-bromoacetophenone compound | 浙江工业大学 | 2025-04-29 | — | — | CN | claimed |
| CN-114950159-B | Preparation method of aromatic polymer separation membrane based on super acid catalysis | 南京工业大学 | 2023-06-06 | — | — | CN | claimed |
| CN-114950159-A | Preparation method of aromatic polymer separation membrane based on super-acid catalysis preparation | 南京工业大学 | 2022-08-30 | — | — | CN | claimed |
| CN-102797043-B | Medicinal molecular fragment library and construction process thereof | Tianli (Tianjin) Technology Co., Ltd. (CN) | 2015-11-25 | — | — | CN | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| CN-102797043-A | Medicinal molecular fragment library and construction method thereof | CBB NETWORK CO LTD | 2012-11-28 | — | — | CN | claimed |
| EP-4735423-A1 | KV7 MODULATORS | Saniona A/S (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731206-A2 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4041732-B1 | ISO-CITRATE DEHYDROGENASE (IDH) INHIBITOR | ZHEJIANG METON PHARMACEUTICAL CO LTD (CN) | 2026-03-18 | — | — | EP | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4532482-B1 | HERBICIDAL DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-20250331519-A1 | HERBICIDAL DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2025-10-30 | — | — | US | disclosed |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | ZHEJIANG METON PHARMACEUTICAL CO., LTD (CN) | 2025-10-14 | — | — | US | disclosed |
| US-5212301-A | SUBSTITUTED FLUOROBENZENES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-05-18 | — | — | US | disclosed |
| EP-0512715-A2 | Verfahren zur Herstellung einer in 3-Stellung fluorierten aromatischen Verbindung | ZENECA LIMITED (GB) | 1992-11-11 | — | — | EP | disclosed |
| US-5138088-A | Nitrobenzoyl-3-cyclopropylaminoacrylates and a process for the preparation thereof | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1992-08-11 | — | — | US | disclosed |
| EP-0016277-B1 | 2-CARBONYL-3-HYDROXY-ALKENONITRILES, THEIR USE AS ANTI-ARTHRITIC AGENTS AND PROCESSES FOR THEIR PREPARATION | AMERICAN CYANAMID COMPANY (US) | 1981-12-02 | — | — | EP | disclosed |
| EP-0016277-A1 | 2-Carbonyl-3-hydroxy-alkenonitriles, their use as anti-arthritic agents and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-10-01 | — | — | EP | disclosed |
| WO-1980000964-A1 | ANTI-INFLAMMATORY AGENTS INCLUDING 2-CARBONYL-3-HYDROXY-2-ALKENONITRILES | AMERICAN CYANAMID CO (US) | 1980-05-15 | — | — | WO | disclosed |
| US-4173650-A | ANTIARTHRITIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1979-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250331519-A1 | HERBICIDAL DERIVATIVES | DDT, CYP1B1, CYP1A1 | CES2 70/4885CES1 96/4885MAOA 623/4885 |
| US-12441725-B2 | ISO-citrate dehydrogenase (IDH) inhibitor | IDH2, IDH3A, IDH1 | CES2 2808/4885CES1 845/4885MAOA 4614/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | CES2 771/4885CES1 223/4885MAOA 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.